Second collaboration with MSD to evaluate combination of BO-112 and KEYTRUDA®
Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis. A collaboration with MSD will focus on the Phase II evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA®...